Dickinson K E, McKernan R M, Miles C M, Leys K S, Sever P S
Eur J Pharmacol. 1986 Jan 29;120(3):285-93. doi: 10.1016/0014-2999(86)90469-3.
[3H]Yohimbine binding to membrane preparations of human colon, cerebral cortex, kidney, spleen and platelets was compared with binding to preparations of animal tissues (rabbit spleen, kidney and cerebral cortex; rat cerebral cortex; guinea-pig and cat spleen). Specific binding to all preparations was saturable and indicative of binding to a uniform population of sites. The equilibrium dissociation constants (KD) of [3H]yohimbine ranged from 1.6 to 2.6 nM for human tissue and from 5.1 to 9.4 nM for the animal tissues. Binding to all tissues was displaced by drugs with an order of potency yohimbine greater than phentolamine greater than prazosin, indicating an alpha 2-adrenoceptor classification of the labelled sites. Whilst certain drugs (phentolamine, corynanthine) possessed similar affinities for all alpha 2-adrenoceptors, others (prazosin, idazoxan, WY 26392) exhibited differential potencies for alpha 2-adrenoceptors in certain species. The pharmacological characteristics of human alpha 2-adrenoceptors were conserved within the tissues examined. These results suggest that human alpha 2-adrenoceptors differ in a number of ways from those present in tissues from the other mammalian species examined. The possible existence of a spectrum of alpha 2-adrenoceptors is discussed in the light of these findings.
将[3H]育亨宾与人结肠、大脑皮层、肾脏、脾脏和血小板的膜制剂的结合,与它与动物组织(兔脾脏、肾脏和大脑皮层;大鼠大脑皮层;豚鼠和猫脾脏)制剂的结合进行了比较。与所有制剂的特异性结合都是可饱和的,表明是与同一类位点结合。[3H]育亨宾的平衡解离常数(KD)在人体组织中为1.6至2.6 nM,在动物组织中为5.1至9.4 nM。与所有组织的结合都被药物取代,取代效力顺序为育亨宾大于酚妥拉明大于哌唑嗪,这表明标记位点属于α2 -肾上腺素能受体类型。虽然某些药物(酚妥拉明、可立那丁)对所有α2 -肾上腺素能受体具有相似的亲和力,但其他药物(哌唑嗪、咪唑克生、WY 26392)在某些物种中对α2 -肾上腺素能受体表现出不同的效力。在所检查的组织中,人α2 -肾上腺素能受体的药理学特征是保守的。这些结果表明,人α2 -肾上腺素能受体在许多方面与所检查的其他哺乳动物物种组织中的α2 -肾上腺素能受体不同。根据这些发现,讨论了α2 -肾上腺素能受体谱可能存在的情况。